Endocrinology of the aging male

Minerva Ginecologica

Volumn 58, Issue 2, 2006, Pages 153-170

  Lunenfeld, B ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Aged; Endocrinology; Male

Indexed keywords

ANDROGEN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PRASTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN;

AGING; BODY COMPOSITION; BODY CONSTITUTION; BODY FAT DISTRIBUTION; BONE DENSITY; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; DEPRESSION; HEALTH BEHAVIOR; HORMONE DEFICIENCY; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LABORATORY TEST; LIFE EXPECTANCY; MUSCLE WEAKNESS; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL DISABILITY; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUALITY; URINE INCONTINENCE;

AGING; ANDROGENS; BODY COMPOSITION; BONE DENSITY; ENDOCRINE GLANDS; HUMANS; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUALITY;

EID: 33646560327     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Lunenfeld B. Aging male. Aging Male 1998;1:1-7.
2. Kalache A, Lunenfeld B. Health and the ageing male. Aging Male 2000;3:1-36.
3. Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. Clin Endocrinol Metab 1997;11:289-30.
4. Vermeulen A. Clinical review 24. Androgens in the aging male. J Clin Endocrinol Metab 1991;73:221-4.
5. Gooren LJL. Endocrine aspects of aging in the male. Mol Cell Endocrinol 1998;145:153-9.
6. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-81.
7. Lunenfeld B. Replacement therapy in the aging male. J Endocrinol Invest 2002;25 (10 Suppl):2-9.
8. Copinschi G, Van Cauter E. Effects of ageing on modulation of hormonal secretion by sleep and circadian rhytmicity. Horm Res 1995;43:20-4.
9. Waldhauser F, Kovacs J, Reiter E. Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Exp Gerontol 1998;33: 759-72.
10. Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med 1993;159:579-85.
11. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:10l6-25.
12. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87: 589-98.
13. Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46: 410-3.
14. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86: 724-31.
15. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6.
16. Snyder PJ. Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med 2004;350:440-2.
17. Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc 2002;50:897-904.
18. Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M et al.: Health ABC Study Investigators. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003;51:1602-9.
19. Baumgartner RN, Stauber PM, McHugh D, Koehler KM, Garry PJ. Cross-sectional age differences in body composition in persons 60+ years of age. J Gerontol A Biol Sci Med Sci 1995;50:M307-16.
20. Kyle UG, Genton L, Hans D, Karsegard VL, Michel JP, Slosman DO et al. Total body mass, fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 60-year-old persons. J Am Geriatr Soc 2001;49:1633-40.
21. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 2004;12:1995-2004.
22. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999;107: 123-36.
23. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr 2004;80:496-503.
24. Perry HM 3rd, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000;49:1085-91.
25. Morley JE, Kaiser FE, Sih R, Hajjar R, Perry HM. Testosterone and frailty. Clin Geriatr Med 1997;13: 685-95.
26. Breuer B, Trungold S, Martucci C, Wallenstein S, Likourezos A, Libow LS et al. Relationships of sex hormone levels to dependence in activities of daily living in the frail elderly. Maturitas 2001;39:147-59.
27. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000;85:3276-82.
28. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407-13.
29. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-7.
30. Morley JE, Perry HM 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41:149-52.
31. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-65.
32. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84: 2647-53.
33. Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C et al. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord 1995;19:614-24.
34. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75: 1092-8.
35. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003;58:618-25.
36. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281:E1172-81.
37. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005;90:678-88.
38. Bhasin S, Storer TW, Singh AB, Woodhouse I, Singh R, Artaza J et al. Testosterone effects on the skeletal muscle. In: Nieschlag E, Behre HM editors. Testosterone: Action, Deficiency, Substitution. Cambridge: Cambridge University Press; 2004. p. 641-64.
39. Savine R, Sonksen PH. Is the somatopause an indication for growth hormone replacement? J Endocrinol Invest 1999;22 (5 Suppl):142-9.
40. Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper MW. Effects of human growth hormone on body composition in elderly men. Horm Res 1991;36 Suppl 1:73-81.
41. Goh VHH, Mu SC, Gao F, Lim KS. Changes in body composition, and endocrine and metabolic functions in healthy elderly Chinese men following growth hormone therapy. Aging Male 1998;1:264-9.
42. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson B-A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81:2865-73.
43. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997;82: 2877-84.
44. Burman P, Broman JE, Hettat J, Wiklund I, Erfurth EM, Hagg E et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80:3585-90.
45. Yarashesky KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995;268:E268-E276.
46. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
47. Haffner SM, Valdez RA, Mykkanen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994;43:599-603.
48. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000;23:490-4.
49. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
50. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 2004;27: 861-8.
51. Tchernof A, Despres JP, Dupont A, Belanger A, Nadeau A, Prud'homme D et al. Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Diabetes Care 1995;18:292-9.
52. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002;87: 4522-7.
53. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992;1: 329-36.
54. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
55. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen- data deprivation therapy. Cancer 2006;106:581-8.
56. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003;67:1521-6.
57. Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urol Oncol 2003;21:380-3.
58. Peris P, Guanabens N. Male osteoporosis. Curr Opin Rheumatol 1996;8:357-64.
59. Boonen S, Vanderschueren D, Geusens P, Bouillon R. Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 1997;20:134-43.
60. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. Clin Endocrinol Metab 1998;83:2266-74.
61. Gurlek A, Gedik O. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover. J Endocrinol Invest 2001;24:408-14.
62. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991;39:766-71.
63. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992;304:4-8.
64. Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol (Oxf) 2004;60:491-9.
65. Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Willvonseder. Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 2001;31:444-51.
66. Kenny AM, Prestwood KM, Marcello KM, Raisz LG. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 2000;55:M492-7.
67. Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003;88:5240-7.
68. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997;12;1833-43.
69. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003;88:5327-33.
70. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
71. Zacharin MR, Pua J, Kanumakala S. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism. Clin Endocrinol (Oxf) 2003;58:691-5.
72. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001;54:739-50.
73. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998;138:51-8.
74. Medras M, Jankowska EA, Rogucka E. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism. Andrologia 2001;33:47-52.
75. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56:M266-72.
76. Francis RM. Androgen replacement in aging men. Calcif Tissue Int 2001;69:235-8.
77. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
78. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:503-10.
79. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003;88:3167-76.
80. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983;57:71-7.
81. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991;53:363-74.
82. Schiavi RC, White D, Mandeli J, Levine AC. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav 1997;26:231-41.
83. O'Carroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry 1984;145:146-51.
84. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-3.
85. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003;139:161-8.
86. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
87. Mills TM, Lewis RW. The role of androgens in the erectile response: a 1999 perspective. Mol Urol 1999;3: 75-86.
88. Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990;71:963-9.
89. Nickel JC, Morales A, Condra M, Fenemore J, Surridge DH. Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 1984;132:40-3.
90. Slag MF, Morley JE, Elson MK, Trence DL, Nelson CJ, Nelson AE et al. Impotence in medical clinic outpatients. JAMA 1983;249:1736-40.
91. Bodie J, Lewis J, Schow D, Monga M. Laboratory evaluations of erectile dysfunction: an evidence based approach. J Urol 2003;169:2262-4.
92. Quay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22:793-7.
93. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R et al. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 2004;46:222-8.
94. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8.
95. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24:381-7.
96. Reilly CM, Lewis RW, Stopper VS, Mills TM. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl 1997;18:588-94.
97. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;53:517-22.
98. Tsujimura A, Matsumiya K, Matsuoka Y, Takahashi T, Koga M, Iwasa A et al. Bioavailable testosterone with age and erectile dysfunction. J Urol 2003;170 (6 Pt 1):2345-7.
99. Ahn HS, Park CM, Lee SW. The clinical relevance of sex hormone levels and sexual activity in the agein male. BJU Int 2002;89:526-30.
100. Rhoden EL, Teloken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002;167:1745-8.
101. Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 2005;95:366-70.
102. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8.
103. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63.
104. Yassin A, Saad F, Diede HE. Combination therapy for erectile dysfunction with testosterone and tadalafil in hypogonadal patients who failed to respond to tadalafil alone. AJU 2003;1:10-2.
105. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9.
106. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8.
107. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173:530-2.
108. Carani C, Granata AR, Bancroft J, Marrama P. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995;20:743-53.
109. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997;158:1764-7.
110. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000;164:371-5.
111. Schultheiss D, Hiltl DM, Meschi MR, Machtens SA, Truss MC, Stief CG et al. Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction. World J Urol 2000;18:431-5.
112. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004;171(6 Pt 1):2358-62.
113. Mulhall JP, Valenzuela R, Aviv N, Parker M. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 2004;63:348-52.
114. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004;171(6 Pt 1):2341-5.
115. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Comprehensive evaluation of erectile dysfunction (ExCEED) database. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the exploratory comprehensive evaluation of erectile dysfunction (ExCEED) database. Diabetes Care 2003; 26:1093-9.
116. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001;87:838-45.
117. Araujo AB, Johannes CB, Feldman HA, Derby CA, McKinlay JB. Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 2000;152:533-41.
118. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol 2003;44:588-94.
119. Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005;47: 511-7.
120. Russell ST, Khandheria BK, Nehra A. Erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2004;79:782-94.
121. Morley JE. Testosterone and behavior. Clin Geriatr Med 2003;19:605-16.
122. Moffat SD, Hampson E. A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology 1996;21:323-37.
123. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999;84:3681-5.
124. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002;87:5001-7.
125. Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc 2002;50:707-12.
126. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001;57:80-8.
127. O'Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on cognitive function in men. Neuropsychologia 2001;39:1385-94.
128. Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 2005;50:124-33.
129. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004;59:75-8.
130. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325-32.
131. Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci 2000;12: 407-14.
132. Almeida OP, Waterreus A, Spry N, Corica T, Martins G, Martins RN et al. Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:823-5.
133. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004;29: 1071-81.
134. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Wang R et al. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci U S A 2000;97:1202-5.
135. Goodenough S, Engert S, Behl C. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci Lett 2000;296:49-52.
136. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004;62:188-93.
137. Bialek M, Zaremba P, Borowicz KK, Czuczwar SJ. Neuroprotective role of testosterone in the nervous system. Pol J Pharmacol 2004;56:509-18.
138. Carnahan RM, Perry PJ. Depression in aging men: the role of testosterone. Drugs Aging 2004;21:361-76.
139. Sachar EJ, Halpern F, Rosenfeld RS, Galligher TF, Hellman L. Plasma and urinary testosterone levels in depressed men. Arch Gen Psychiatry 1973;28:15-8.
140. Shaw DM, Francis AF, Groom GV, Riad-Fahmy D. A pilot endocrine study in depression. Postgrad Med J 1977;53 Suppl 4:172-4.
141. Steiger A, von Bardeleben U, Wiedemann K, Holsboer F. Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J Psychiatr Res 1991;25:169-77.
142. Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry 2001;62:406-12.
143. Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry 2005;66:7-14.
144. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:573-7.
145. Perry PJ, Lund BC, Arndt S, Holman T, Bever-Stille KA, Paulsen J et al. Bioavailable testosterone as a correlate of cognition, psychological status, quality of life, and sexual function in aging males: implications for testosterone replacement therapy. Ann Clin Psychiatry 2001;13:75-80.
146. Seidman SN, Araujo AB, Roose SP, Devanand DP, Xie S, Cooper TB et al. Low testosterone levels in elderly men with dysthymic disorder. Am J Psychiatry 2002;159:456-9.
147. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004;61:162-7.
148. Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry 2001;50:371-6.
149. Krithivas K, Yurgalevitch SM, Mohr BA, Wilcox CJ, Batter SJ, Brown M et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 1999;162:137-42.
150. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V et al. Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996;81:3578-83.
151. Perry PJ, Yates WR, Williams RD, Andersen AE, MacIndoe JH, Lund BC et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry 2002;63:1096-101.
152. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998;48:157-61.
153. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:105-11.